Chemotherapy‐induced phlebitis via GBP5/NLRP3 axis and the therapeutic effect of Aescin

Peng Liu,Lichun Ye,Yongshen Ren,Guodun Zhao,Yun Zhang,Shaojuan Lu,Qiang Li,Chen Wu,Lijie Bai,Zhongyun Zhang,Zhongqiu Zhao,Zhaohua Shi,Shijin Yin,Maochuan Liao,Zhou Lan,Jing Feng,Lvyi Chen
DOI: https://doi.org/10.1111/bph.16002
IF: 7.3
2022-12-09
British Journal of Pharmacology
Abstract:Background and Purpose Intravenous infusion of chemotherapy drugs can cause severe chemotherapy‐induced phlebitis (CIP) in patients. However, the underlying mechanism of CIP remains unclear. Experimental Approach RNA‐seq analysis to identify potential disease target in CIP. GBP5 genetic deletion approaches were used to investigate the role of GBP5 in NLRP3 inflammasome activation in lipopolysaccharides (LPS)‐primed bone‐marrow‐derived macrophages (BMDMs) induced by vinorelbine (VIN) in vitro and in mouse models of VIN‐induced CIP in vivo. The anti‐CIP effect of aescin was evaluated in vivo and in vivo. Key Results Here, we showed that the expression of guanylate binding protein 5 (GBP5), was upregulated in PBMCs from CIP patients. Genetic ablation of GBP5 from macrophages significantly alleviated VIN‐induced CIP in the experimental mouse model. Mechanistically, GBP5 contributed to the inflammatory responses through activating NLRP3 inflammasome and driving the production of inflammatory cytokine IL‐1β. Moreover, aescin, a mixed triterpene saponin extracted from horse chestnut seed, can alleviate CIP by inhibiting the GBP5/NLRP3 axis. Conclusion and Implications These findings suggest that GBP5 is an important regulator of NLRP3 inflammasome in CIP mouse model. Our work further reveals that aescin may serve as a promising candidate in the clinical treatment of CIP.
pharmacology & pharmacy
What problem does this paper attempt to address?